Patients with asymptomatic hyperuricemia complicated by chronic kidney disease stage 3

Randomization through the dynamic allocation procedure using allocation factors (study site, gender, age, serum uric acid, proteinuria, and complication by diabetes mellitus)

Randomization
N = 400, 1:1

Febuxostat group (N = 200)
10-mg tablet/day at weeks 1-4 after initiation
20-mg tablet/day at weeks 5-8 after initiation
40-mg tablet/day thereafter

Placebo group (N = 200)
10-mg tablet/day at weeks 1-4 after initiation
20-mg tablet/day at weeks 5-8 after initiation
40-mg tablet/day thereafter

Study drug administration for 108 weeks
Primary endpoint: eGFR slope (mL/min/1.73 m²/year)